You just read:

Aurigene to Present its Programs on Covalent, Selective CDK7 Inhibitors, Novel Peptide Antagonists of CD47-SIRPα Interaction and Inhibitors of MALT-1 Signalling at the AACR 2017

News provided by

Aurigene Discovery Technologies Limited

31 Mar, 2017, 07:09 BST